AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Monopar Therapeutics Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00J7K8DB7
70.65▼ 1.93 (-2.66%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
72.58
Day's Range
69.48 – 71.84
52-Week Range
49.50 – 124.82
Volume
85.7K
Avg Volume
148.6K
Share Statistics
Shares Outstanding
Employees
22
Exchange
XNAS
Listed
2019-12-19
Share count as of July 31, 2026

Monopar Therapeutics Inc. Common Stock (MNPR) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Monopar Therapeutics Inc. Common Stock (MNPR)
What is Monopar Therapeutics Inc. Common Stock's Market Cap?
Monopar Therapeutics Inc. Common Stock's Market Cap is $474.2M, based on as-reported figures from SEC (XBRL) filings.
What is Monopar Therapeutics Inc. Common Stock's Enterprise Value?
Monopar Therapeutics Inc. Common Stock's Enterprise Value is $421.5M, based on as-reported figures from SEC (XBRL) filings.
What is Monopar Therapeutics Inc. Common Stock's Revenue (TTM)?
Monopar Therapeutics Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Monopar Therapeutics Inc. Common Stock's Net Income (TTM)?
Monopar Therapeutics Inc. Common Stock's Net Income (TTM) is -$17.8M, based on as-reported figures from SEC (XBRL) filings.
What is Monopar Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
Monopar Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -2.66, based on as-reported figures from SEC (XBRL) filings.
What is Monopar Therapeutics Inc. Common Stock's Net Debt?
Monopar Therapeutics Inc. Common Stock's Net Debt is -$52.8M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MNPRAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Research and development
General and administrative
Total operating expenses
Income (loss) from operations
Other income (loss)—
Interest income (loss)
Net income (loss)
Basic and diluted (in dollars per share)